SG11202103781TA - Products, uses & methods - Google Patents

Products, uses & methods

Info

Publication number
SG11202103781TA
SG11202103781TA SG11202103781TA SG11202103781TA SG11202103781TA SG 11202103781T A SG11202103781T A SG 11202103781TA SG 11202103781T A SG11202103781T A SG 11202103781TA SG 11202103781T A SG11202103781T A SG 11202103781TA SG 11202103781T A SG11202103781T A SG 11202103781TA
Authority
SG
Singapore
Prior art keywords
products
methods
Prior art date
Application number
SG11202103781TA
Inventor
Virginia Martinez
Ruben Vazquez-Uribe
Adam Takos
Der Helm Eric Van
Jasper Clube
Original Assignee
Snipr Biome Aps
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB1816700.7A external-priority patent/GB201816700D0/en
Priority claimed from GBGB1817509.1A external-priority patent/GB201817509D0/en
Application filed by Snipr Biome Aps filed Critical Snipr Biome Aps
Publication of SG11202103781TA publication Critical patent/SG11202103781TA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/70—Vectors or expression systems specially adapted for E. coli
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/465—Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Clostridium (G)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/102—Mutagenizing nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/74—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/22—Ribonucleases RNAses, DNAses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/20—Type of nucleic acid involving clustered regularly interspaced short palindromic repeats [CRISPRs]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/80—Vectors containing sites for inducing double-stranded breaks, e.g. meganuclease restriction sites
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2820/00—Vectors comprising a special origin of replication system
    • C12N2820/002—Vectors comprising a special origin of replication system inducible or controllable
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2820/00—Vectors comprising a special origin of replication system
    • C12N2820/007—Vectors comprising a special origin of replication system tissue or cell-specific
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2820/00—Vectors comprising a special origin of replication system
    • C12N2820/55—Vectors comprising a special origin of replication system from bacteria
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/001—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination
    • C12N2830/005—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination repressible enhancer/promoter combination, e.g. KRAB
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/20—Vector systems having a special element relevant for transcription transcription of more than one cistron
SG11202103781TA 2018-10-14 2019-10-14 Products, uses & methods SG11202103781TA (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GBGB1816700.7A GB201816700D0 (en) 2018-10-14 2018-10-14 Products, uses & methods
GBGB1817509.1A GB201817509D0 (en) 2018-10-27 2018-10-27 Products, uses & methods
US16/201,736 US11851663B2 (en) 2018-10-14 2018-11-27 Single-vector type I vectors
PCT/EP2019/077760 WO2020078893A1 (en) 2018-10-14 2019-10-14 Products, uses & methods

Publications (1)

Publication Number Publication Date
SG11202103781TA true SG11202103781TA (en) 2021-05-28

Family

ID=70159814

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202103781TA SG11202103781TA (en) 2018-10-14 2019-10-14 Products, uses & methods

Country Status (12)

Country Link
US (3) US11851663B2 (en)
EP (3) EP4170036A1 (en)
JP (1) JP2022512695A (en)
KR (1) KR20210076952A (en)
CN (1) CN113423835A (en)
AU (1) AU2019362312A1 (en)
BR (1) BR112021007003A2 (en)
CA (1) CA3115910A1 (en)
DE (1) DE112019005139T5 (en)
IL (1) IL282178A (en)
SG (1) SG11202103781TA (en)
WO (1) WO2020078893A1 (en)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016177682A1 (en) 2015-05-06 2016-11-10 Snipr Technologies Limited Altering microbial populations & modifying microbiota
GB201609811D0 (en) 2016-06-05 2016-07-20 Snipr Technologies Ltd Methods, cells, systems, arrays, RNA and kits
GB201712733D0 (en) 2017-08-08 2017-09-20 Snipr Tech Ltd Methods & cells
US10760075B2 (en) 2018-04-30 2020-09-01 Snipr Biome Aps Treating and preventing microbial infections
US11851663B2 (en) 2018-10-14 2023-12-26 Snipr Biome Aps Single-vector type I vectors
GB202007943D0 (en) 2020-05-27 2020-07-08 Snipr Biome Aps Products & methods
GB202015255D0 (en) 2020-09-26 2020-11-11 Snipr Biome Aps Synthetic viruses
WO2022082362A1 (en) * 2020-10-19 2022-04-28 陈振暐 Non-pathogenic bacterial gene expression system and transformant for metabolizing tyrosine, use thereof for preparing composition for reducing urinary toxins, and method for metabolizing tyrosine using same
EP4346881A1 (en) * 2021-05-26 2024-04-10 The Regents of The University of Michigan Crispr-cas3 systems for targeted genome engineering
AU2022331230A1 (en) * 2021-08-20 2024-03-21 Gra&Green Inc. Polynucleotide including site-specific nuclease expression cassette

Family Cites Families (88)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4626504A (en) 1983-07-01 1986-12-02 Lubrizol Genetics, Inc. DNA transfer vector for gram-negative bacteria
DE4208785A1 (en) 1992-03-19 1993-09-23 Degussa METHOD FOR DETECTING INSERTION ELEMENTS (IS ELEMENTS) OR TRANSPOSONS
AU2002365188A1 (en) 2001-11-07 2003-07-30 Musc Foundation For Research Development Nucleic acid delivery and expression
CA2396611A1 (en) 2002-07-31 2004-01-31 Plant Bioscience Limited Materials and methods for generating genetic disruptions in bacterial cells
WO2005046579A2 (en) 2003-10-06 2005-05-26 Gangagen, Inc. Defined dose therapeutic phage
PT1916903E (en) 2005-08-26 2010-09-03 Danisco Use of crispr associated genes (cas)
US8445639B2 (en) 2006-05-15 2013-05-21 Avidbiotics Corporation Recombinant bacteriophage and methods for their use
ES2719789T3 (en) 2007-03-02 2019-07-16 Dupont Nutrition Biosci Aps Crops with improved phage resistance
WO2010011961A2 (en) 2008-07-25 2010-01-28 University Of Georgia Research Foundation, Inc. Prokaryotic rnai-like system and methods of use
WO2010075424A2 (en) 2008-12-22 2010-07-01 The Regents Of University Of California Compositions and methods for downregulating prokaryotic genes
US8241498B2 (en) 2009-03-28 2012-08-14 Phage Biocontrol Research, Llc Process for remediating biofouling in water systems with virulent bacteriophage
US8252576B2 (en) 2010-08-11 2012-08-28 Phage Biocontrol Research, Llc Use of prokaryote viruses to remediate bio-fouling
JP5947311B2 (en) 2010-12-09 2016-07-06 ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア Use of chimeric antigen receptor modified T cells for the treatment of cancer
US9730967B2 (en) 2011-02-04 2017-08-15 Katherine Rose Kovarik Method and system for treating cancer cachexia
WO2012164565A1 (en) 2011-06-01 2012-12-06 Yeda Research And Development Co. Ltd. Compositions and methods for downregulating prokaryotic genes
CA2853707A1 (en) 2011-10-28 2013-05-02 Regeneron Pharmaceuticals, Inc. Genetically modified t cell receptor mice
US9637739B2 (en) 2012-03-20 2017-05-02 Vilnius University RNA-directed DNA cleavage by the Cas9-crRNA complex
JP6562837B2 (en) 2012-04-30 2019-08-21 ソノマシューティカルズ・エルエルシー The therapeutic use of Chardonnay seed products
CN113967253A (en) 2012-05-15 2022-01-25 百时美施贵宝公司 Immunotherapy by disrupting PD-1/PD-L1 signaling
JP6343605B2 (en) 2012-05-25 2018-06-13 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア Methods and compositions for RNA-dependent target DNA modification and RNA-dependent transcriptional regulation
WO2013187556A1 (en) 2012-06-14 2013-12-19 Scripps Korea Antibody Institute Novel antibody specific for clec14a and uses thereof
MX2015000433A (en) 2012-07-13 2016-04-28 Univ Pennsylvania Use of cart19 to deplete normal b cells to induce tolerance.
PL3494997T3 (en) 2012-07-25 2020-04-30 The Broad Institute, Inc. Inducible dna binding proteins and genome perturbation tools and applications thereof
US11060148B2 (en) 2012-10-16 2021-07-13 Dana-Farber Cancer Institute, Inc. Diagnosing and treating colorectal cancer
KR20150105635A (en) 2012-12-12 2015-09-17 더 브로드 인스티튜트, 인코퍼레이티드 Crispr-cas component systems, methods and compositions for sequence manipulation
WO2014093694A1 (en) 2012-12-12 2014-06-19 The Broad Institute, Inc. Crispr-cas nickase systems, methods and compositions for sequence manipulation in eukaryotes
US8697359B1 (en) 2012-12-12 2014-04-15 The Broad Institute, Inc. CRISPR-Cas systems and methods for altering expression of gene products
US10660943B2 (en) 2013-02-07 2020-05-26 The Rockefeller University Sequence specific antimicrobials
EP3011035B1 (en) * 2013-06-17 2020-05-13 The Broad Institute, Inc. Assay for quantitative evaluation of target site cleavage by one or more crispr-cas guide sequences
US20160145645A1 (en) * 2013-06-19 2016-05-26 Sigma-Aldrich Co. Llc Targeted integration
WO2015034872A2 (en) 2013-09-05 2015-03-12 Massachusetts Institute Of Technology Tuning microbial populations with programmable nucleases
SG11201602979RA (en) 2013-10-17 2016-05-30 Univ Singapore Chimeric receptor that triggers antibody-dependent cell cytotoxicity against multiple tumors
US10144770B2 (en) 2013-10-17 2018-12-04 National University Of Singapore Chimeric receptors and uses thereof in immune therapy
US10752906B2 (en) 2013-11-05 2020-08-25 President And Fellows Of Harvard College Precise microbiota engineering at the cellular level
EP3375877A1 (en) 2013-11-18 2018-09-19 Crispr Therapeutics AG Crispr-cas system materials and methods
KR102170502B1 (en) 2013-12-11 2020-10-28 리제너론 파마슈티칼스 인코포레이티드 Methods and compositions for the targeted modification of a genome
AU2014361826A1 (en) * 2013-12-12 2016-06-23 Massachusetts Institute Of Technology Delivery, use and therapeutic applications of the CRISPR-Cas systems and compositions for targeting disorders and diseases using particle delivery components
EP3099173A4 (en) 2014-01-29 2017-09-20 Synphagen LLC. Therapeutic phages and methods for delivery of nucleic acids for therapeutic uses
RU2690670C2 (en) 2014-03-12 2019-06-05 Ида Рисерч Энд Дивелопмент Ко., Лтд Reduced levels or activity of systemic regulatory t cells for treating disease or cns injury
AU2015231413B2 (en) 2014-03-19 2020-04-23 Infinity Pharmaceuticals, Inc. Heterocyclic compounds for use in the treatment of PI3K-gamma mediated disorders
EP3122870B1 (en) 2014-03-25 2022-06-29 Ginkgo Bioworks Inc. Methods and genetic systems for cell engineering
EP3126503A1 (en) 2014-04-03 2017-02-08 Massachusetts Institute Of Technology Methods and compositions for the production of guide rna
JP2017512481A (en) 2014-04-08 2017-05-25 ノースカロライナ ステート ユニバーシティーＮｏｒｔｈ Ｃａｒｏｌｉｎａ Ｓｔａｔｅ Ｕｎｉｖｅｒｓｉｔｙ Methods and compositions for RNA-dependent transcriptional repression using CRISPR-related genes
JP6849435B2 (en) 2014-04-14 2021-03-24 ネメシス バイオサイエンス リミティド Therapeutic
GB201406968D0 (en) 2014-04-17 2014-06-04 Green Biologics Ltd Deletion mutants
GB201406970D0 (en) 2014-04-17 2014-06-04 Green Biologics Ltd Targeted mutations
EP3166974A1 (en) 2014-07-11 2017-05-17 Genentech, Inc. Anti-pd-l1 antibodies and diagnostic uses thereof
EP3186368B1 (en) 2014-08-25 2020-01-15 Geneweave Biosciences Inc. Non-replicative transduction particles and transduction particle-based reporter systems
EP3633032A3 (en) 2014-08-28 2020-07-29 North Carolina State University Novel cas9 proteins and guiding features for dna targeting and genome editing
EP3659621A1 (en) 2014-09-13 2020-06-03 Novartis AG Combination therapies for cancer
CA2959428A1 (en) 2014-09-19 2016-03-24 Regeneron Pharmaceuticals, Inc. Chimeric antigen receptors
US10920208B2 (en) 2014-10-22 2021-02-16 President And Fellows Of Harvard College Evolution of proteases
AU2015334468B2 (en) 2014-10-23 2021-06-17 Institut Gustave Roussy Methods and products for modulating microbiota composition for improving the efficacy of a cancer treatment with an immune checkpoint blocker
WO2016100882A1 (en) 2014-12-19 2016-06-23 Novartis Ag Combination therapies
WO2016177682A1 (en) 2015-05-06 2016-11-10 Snipr Technologies Limited Altering microbial populations & modifying microbiota
GB2531454A (en) 2016-01-10 2016-04-20 Snipr Technologies Ltd Recombinogenic nucleic acid strands in situ
US20160347836A1 (en) 2015-05-28 2016-12-01 Bristol-Myers Squibb Company Treatment of hodgkin's lymphoma using an anti-pd-1 antibody
US10136649B2 (en) 2015-05-29 2018-11-27 North Carolina State University Methods for screening bacteria, archaea, algae, and yeast using CRISPR nucleic acids
CA2987129A1 (en) 2015-06-01 2016-12-08 The University Of Chicago Treatment of cancer by manipulation of commensal microflora
FI3307872T3 (en) 2015-06-15 2023-10-16 Univ North Carolina State Methods and compositions for efficient delivery of nucleic acids and rna-based antimicrobials
EP3322797B1 (en) 2015-07-13 2023-11-29 Institut Pasteur Improving sequence-specific antimicrobials by blocking dna repair
GB201514510D0 (en) 2015-08-14 2015-09-30 Nemesis Bioscience Ltd Delivery vehicle
EP3943093A1 (en) 2015-09-10 2022-01-26 Université catholique de Louvain Use of pasteurized akkermansia for treating cancer
WO2017058751A1 (en) 2015-09-28 2017-04-06 North Carolina State University Methods and compositions for sequence specific antimicrobials
US10947559B2 (en) 2015-10-16 2021-03-16 Astrazeneca Ab Inducible modification of a cell genome
US11542466B2 (en) 2015-12-22 2023-01-03 North Carolina State University Methods and compositions for delivery of CRISPR based antimicrobials
TWI808055B (en) 2016-05-11 2023-07-11 美商滬亞生物國際有限公司 Combination therapies of hdac inhibitors and pd-1 inhibitors
GB201609811D0 (en) 2016-06-05 2016-07-20 Snipr Technologies Ltd Methods, cells, systems, arrays, RNA and kits
AU2017335732A1 (en) 2016-09-27 2019-04-04 Board Of Regents, The University Of Texas System Methods for enhancing immune checkpoint blockade therapy by modulating the microbiome
IT201600102542A1 (en) 2016-10-12 2018-04-12 Univ Degli Studi Di Trento Plasmid and lentiviral system containing a self-limiting Cas9 circuit that increases its safety.
WO2018081502A1 (en) 2016-10-28 2018-05-03 Massachusetts Intitute Of Technology Synthetic bacteriophages and bacteriophage compositions
EP3358015A1 (en) * 2017-02-03 2018-08-08 Eligo Bioscience Optimized vector for delivery in microbial populations
WO2018217351A1 (en) 2017-05-24 2018-11-29 Tets Viktor Veniaminovich Methods for treating and preventing diseases
WO2018217981A1 (en) 2017-05-26 2018-11-29 North Carolina State University Altered guide rnas for modulating cas9 activity and methods of use
WO2018222969A1 (en) 2017-06-02 2018-12-06 Board Of Regents, The University Of Texas System Specific bacterial species and metabolite that improves immune checkpoint inhibitor therapy efficacy
WO2018226853A1 (en) 2017-06-07 2018-12-13 The Rockefeller University Enhancement of crispr gene editing or target destruction by co-expression of heterologous dna repair protein
GB201710126D0 (en) 2017-06-25 2017-08-09 Snipr Tech Ltd Vectors & Methods
CN111051510A (en) 2017-06-25 2020-04-21 斯尼普技术有限公司 Altering microbial populations and modifying microbial populations
GB201712733D0 (en) 2017-08-08 2017-09-20 Snipr Tech Ltd Methods & cells
CN107557378A (en) 2017-09-19 2018-01-09 安徽大学 Gene cas7 3 eukaryotic gene edit methods in a kind of type CRISPR Cas systems based on I
US20190160120A1 (en) 2017-11-29 2019-05-30 Snipr Biome Aps Dna, methods etc
US10760075B2 (en) 2018-04-30 2020-09-01 Snipr Biome Aps Treating and preventing microbial infections
FR3081881A1 (en) 2018-06-04 2019-12-06 IFP Energies Nouvelles OPTIMIZED GENETIC TOOL FOR MODIFYING CLOSTRIDIUM BACTERIA
WO2020072253A1 (en) 2018-10-01 2020-04-09 North Carolina State University Recombinant type i crispr-cas system and uses thereof for screening for variant cells
WO2020072250A1 (en) 2018-10-01 2020-04-09 North Carolina State University Recombinant type i crispr-cas system and uses thereof for genome modification and alteration of expression
US10711267B2 (en) * 2018-10-01 2020-07-14 North Carolina State University Recombinant type I CRISPR-Cas system
US20220170048A1 (en) 2018-10-01 2022-06-02 North Carolina State University Recombinant type i crispr-cas system and uses thereof for killing target cells
US11851663B2 (en) 2018-10-14 2023-12-26 Snipr Biome Aps Single-vector type I vectors

Also Published As

Publication number Publication date
US20210163960A1 (en) 2021-06-03
US11851663B2 (en) 2023-12-26
AU2019362312A1 (en) 2021-05-20
DE112019005139T5 (en) 2021-07-15
EP4170036A1 (en) 2023-04-26
US20210189406A1 (en) 2021-06-24
WO2020078893A1 (en) 2020-04-23
KR20210076952A (en) 2021-06-24
US11629350B2 (en) 2023-04-18
US11578333B2 (en) 2023-02-14
IL282178A (en) 2021-05-31
EP3636763A1 (en) 2020-04-15
CN113423835A (en) 2021-09-21
CA3115910A1 (en) 2020-04-23
JP2022512695A (en) 2022-02-07
BR112021007003A2 (en) 2021-07-27
EP3831947A1 (en) 2021-06-09
US20200115716A1 (en) 2020-04-16

Similar Documents

Publication Publication Date Title
IL282178A (en) Products, uses & methods
GB201916874D0 (en) .
FI3265123T3 (en) Antibodies, uses & methods
EP3177744A4 (en) Material, method&component
GB2577981B (en) Methods, products & Uses relating thereto
GB201813648D0 (en) Methods, products & uses relating thereto
EP3178803A4 (en) Method for preparing 2,3,3,3-tetrafluoropropene
SG11201803584RA (en) 1,4-dicarbonyl-piperidyl derivatives
HK1254800A1 (en) 2,3,4,5-tetrahydropyridin-6-amine derivatives
GB201912021D0 (en) Methods, products & Uses relating thereto
GB201917115D0 (en) .
GB201916765D0 (en) .
FI3592723T3 (en) Process for preparing 3,3,3-trifluoroprop-1-ene
GB201817509D0 (en) Products, uses & methods
GB201816700D0 (en) Products, uses & methods
GB201912016D0 (en) Methods, products & uses relating thereto
GB201715900D0 (en) Palate-transducers & palate-loudspeakers, new drawings
GB201815698D0 (en) .
GB201814103D0 (en) .
GB201600418D0 (en) Products, uses & methods (1.2)
GB201518402D0 (en) Products, uses & methods (8)
GB201510891D0 (en) Products, uses & methods (7)
GB201509366D0 (en) Products, uses & methods (6)
GB201507774D0 (en) Products, uses & methods (2)
GB201507776D0 (en) Products, uses & methods (4)